Description: Discussion of the evolving role of reinsurance in driving business decisions for the direct side, with particular emphasis on underwriting and risk classification and the emphasis on automatic versus facultative business.

Description: The excess capacity that has triggered structural reinsurance market shifts has companies focusing on uninsured and underinsured exposures to tackle the issue.

Description: Q&A with President Life & Health US. Swiss Re. Neil Sprackling.

Description: Characteristics of natural catastrophes and management thereof.

Description: Overview of the diverse Asia markets and four key themes:Rapid pace of product development, innovative underwriting solutions, Wellness, the rise of insurtech.

Description: Jeff Poulin is the CEO of Canada Life Re, a division of Great West Life Assurance Company. He was appointed CEO in May 2017, but he has been working for the reinsurance company since 1991.

Description: Discussion of the increased use of reinsurance in the life insurance industry, including the causes and implications

Description: The March 2013 issue of Reinsurance News

Description: This presentation discusses a process for determining the minimum reinsurance retention level consistent with defined parameters. The conclusions reached were: 1. Under PDS dependence, optimal reinsurance strategy is multivariate stop loss form. 2. Explicit solutions could be derived in certain bivariate model. 3. Binding and unbinding constraints are equivalent. From Actuarial Research Clearing House, 2012, Vol. 1.

Description: The presenters describe the process payers and employers can use to evaluate emerging medical device technologies, recent or pending FDA submissions for prescription drugs and experimental treatments that impact patient care, resource utilization and health care expenditures. Learn the process of identifying and selecting impactful treatments (Horizon Scanning) and quantifying the financial cost of new technologies before they arrive in the market. These workflows can be leveraged by actuaries, healthcare economists, clinicians and pharmacists from a payer (Commercial and Medicare) and employer perspective for self-funded plans. Walk through sample models that illustrate how costs for emerging technologies and treatments can be modeled.